Evidence-based use of indomethacin and ibuprofen in the neonatal intensive care unit.

Johnston PG, Gillam-Krakauer M, Fuller MP, Reese J
Clin Perinatol. 2012 39 (1): 111-36

PMID: 22341541 · PMCID: PMC3598606 · DOI:10.1016/j.clp.2011.12.002

Indomethacin and ibuprofen are potent inhibitors of prostaglandin synthesis. Neonates have been exposed to these compounds for more than 3 decades. Indomethacin is commonly used to prevent intraventricular hemorrhage (IVH), and both drugs are prescribed for the treatment or prevention of patent ductus arteriosus (PDA). This review examines the basis for indomethacin and ibuprofen use in the neonatal intensive care population. Despite the call for restrained use of each drug, the most immature infants are likely to need pharmacologic approaches to reduce high-grade IVH, avoid the need for PDA ligation, and preserve the opportunity for an optimal outcome.

Copyright © 2012 Elsevier Inc. All rights reserved.

MeSH Terms (10)

Cyclooxygenase Inhibitors Ductus Arteriosus, Patent Evidence-Based Medicine Humans Ibuprofen Indomethacin Infant, Newborn Infant, Newborn, Diseases Infant, Premature Intensive Care Units, Neonatal

Connections (1)

This publication is referenced by other Labnodes entities:

Links